Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis

British Journal of Surgery

Volumn 101, Issue 6, 2014, Pages 653-660

  Tsuburaya, A ^a   Mizusawa, J ^b   Tanaka, Y ^c   Fukushima, N ^d   Nashimoto, A ^e   Sasako, M ^f  

^a SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c Saitama Cancer Centre   (Japan)

^d Yamagata Prefectural Central Hospital   (Japan)

^e NIIGATA CANCER CENTER HOSPITAL   (Japan)

^f HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEMALE; GASTRECTOMY; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; STOMACH TUMOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DRUG COMBINATIONS; FEMALE; GASTRECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEUTROPENIA; OXONIC ACID; POSTOPERATIVE COMPLICATIONS; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 84898548268     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9484     Document Type: Article

References (20)

1. Sasako M., Role of surgery in multidisciplinary treatment for solid cancers. Int J Clin Oncol 2004; 9: 346-351.
2. Okines AF, Cunningham D,. Multimodality treatment for localized gastro-oesophageal cancer. Ann Oncol 2010; 21 (Suppl 7): vii286-vii293.
3. Biondi A, Persiani R, Cananzi F, Zoccali M, Vigorita V, Tufo A, et-al. R0 resection in the treatment of gastric cancer: room for improvement. World J Gastroenterol 2010; 16: 3358-3370.
4. Biondi A, Hyung WJ,. Seventh edition of TNM classification for gastric cancer. J Clin Oncol 2011; 29: 4338-4339.
5. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma-2nd English edition-response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. Gastric Cancer 2001; 4: 1-8.
6. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14: 101-112.
7. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et-al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359: 453-462.
8. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et-al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol 2004; 22: 2767-2773.
9. Miyagaki H, Fujitani K, Tsujinaka T, Hirao M, Yasui M, Kashiwazaki M, et-al. The significance of gastrectomy in advanced gastric cancer patients with non-curative factors. Anticancer Res 2008; 28: 2379-2384.
10. Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, et-al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 2009; 96: 1015-1022.
11. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et-al.; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10: 1063-1069.
12. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et-al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.
13. Bonilla L, Ben-Aharon I, Vidal L, Gafter-Grili A, Leibovici L, Stemmer SM,. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 2010; 102: 1845-1854.
14. Neoadjuvant Chemotherapy for Cervical Cancer Meta-Analysis (NACCCMA) Collaboration. Neoadjuvant chemotherapy for locally advanced cervix cancer. Cochrane Database Syst Rev 2004; (2)CD001774.
15. Iwasaki Y, Sasako M, Yamamoto S, Nakamura K, Sano T, Katai H, et-al.; Gastric Cancer Surgical Study Group of Japan Clinical Oncology Group. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol 2013; 107: 741-745.
16. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113-123.
17. National Cancer Institute. Common Toxicity Criteria (CTC) Version 2.0. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcv20-4-30-992.pdf [accessed 25 February 2014 ].
18. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et-al.; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
19. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et-al.; Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
20. Katayama H, Ito S, Sano T, Takahari D, Mizusawa J, Boku N, et-al.; Stomach Cancer Study Group of the Japan Clinical Oncology Group. A phase II study of systemic chemotherapy with docetaxel, cisplatin, and S-1 (DCS) followed by surgery in gastric cancer patients with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1002. Jpn J Clin Oncol 2012; 42: 556-559.